Compare Adaptive Biotechnologies Corp (ADPT) vs Teradyne, Inc. (TER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Teradyne, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.03 (market cap $3.33B), while Teradyne, Inc. trades at $344.81 (market cap $53.71B). The key difference: Teradyne, Inc. is far larger — about 16.1× Adaptive Biotechnologies Corp's market cap, and Teradyne, Inc. pays a 0.15% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | TER | |
|---|---|---|
Market Cap | $3.33B | $53.71B |
Sector | Health | Technology |
52-Week High | $22.37 | $483.84 |
52-Week Low | $10.24 | $90.15 |
Enterprise Value | $3.19B | $53.55B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Teradyne (TER) trades at $343.11, down 7.04% amid a semiconductor sector sell-off, yet maintains strong fundamentals with 22.55% net margins and consistent earnings beats. The stock shows bearish technical signals but benefits from robust AI-driven demand, with 64.5% analyst buy ratings and a $453.60 consensus target suggesting 32% upside. Recent dividend declaration and strong cash flow generation support long-term stability despite near-term volatility.
Outlook remains positive given Teradyne's leadership in semiconductor testing and robotics, with AI infrastructure spending driving growth. Risks include sector cyclicality and premium valuations (P/E 70.4), but earnings momentum and institutional support provide cushion. The stock presents a compelling opportunity for investors seeking AI infrastructure exposure with proven execution capabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
